Compare Summit Therapeutics Inc (SMMT) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Vanguard Total Stock Market Index Fund ETF trades at $369.26. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VTI | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | — |
52-Week High | $29.32 | $374.36 |
52-Week Low | $13.05 | $305.74 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF offers broad exposure to the entire U.S. stock market with over 3,500 holdings and a low 0.03% expense ratio. Recent news highlights its role in long-term portfolios and inclusion in new tax-advantaged accounts, emphasizing diversification benefits.
Outlook remains positive for long-term investors due to historical performance and cost efficiency, but near-term risks include market volatility and potential underperformance if large-cap tech stocks weaken. The bearish technical setup suggests caution for short-term traders, while fundamentals support holding for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
